←
Eric Green366 posts
Eric Green avatar

Eric Green

@ercgrn

Physician-scientist-entrepreneur. Biotech CEO/CSO. Genetics, biotech, birds (mostly raptors), books.

◷ Joined January 2011▧ 22 Photos and videos
FrattaLab avatar
⟳ Eric Green retweeted
FrattaLab@FrattaLab·24 Jun 2024

We find TDP-43 loss to cause presynaptic defects, which are rescued by ASOs correcting a single cryptic exon in UNC13A. Surprising effect of just one cryptic exon and promising strategy for ALS! Matt Keuss @PeteHarley95 in great collaboration with @jbneuro biorxiv.org/content/10.1101/…

Eric Green avatar
Eric Green@ercgrn·22 May 2024

Nice example of integrating human genetics, functional genomics and protein structure to understand disease biology. Congrats @artwuster @karls_es and team.

There are haploinsufficiencies that are caused almost entirely by missense variants instead of truncating mutations. Those genes are more vulnerable to missense variants disrupting their function, and SLC6A1 is an example. Here's our paper: cell.com/ajhg/fulltext/S0002…

Michael Baym avatar
⟳ Eric Green retweeted
Michael Baym@baym·19 Jan 2024

If there was only one scientific practice I could teach to every scientist regardless of stage or field I think it would be: look at the data. Spot check it. Find a few data points and trace them through to see if they make sense. Look at the raw data. Don't just do analyses.

Eric Green avatar
Eric Green@ercgrn·18 Jan 2024

We show that inhibiting glycogen synthase (SRT) reduces glycogen accumulation and corrects muscle metabolism in a mouse model of Pompe, as monotherapy or combined with enzyme replacement (ERT). 2/3

Post attachment
Daniel J Drucker avatar
⟳ Eric Green retweeted
Daniel J Drucker@DanielJDrucker·17 Jan 2024

Here, substrate reduction therapy with GYS1 inhibition may be a promising therapeutic approach for Pompe disease and other glycogen storage diseases @ScienceTM science.org/doi/10.1126/scit…

Eric Green avatar
Eric Green@ercgrn·6 Oct 2023

Initial data on our small molecule APOL1 pore inhibitor shared at @ASNKidney 2022 with exciting updates to come at Kidney Week 2023. We expect to enter the clinic this year.

Post attachment
Eric Green avatar
Eric Green@ercgrn·6 Oct 2023

Study ids and functionalizes a renal protective variant in APOL1, implicating ion conductance as pathologic mechanism for APOL1 kidney dz. This mechanism has been further validated by @VertexPharma POC study of APOL1 pore inhibitor in FSGS @NEJM.

Post attachment
Eric Green avatar
Eric Green@ercgrn·6 Oct 2023

New pub from our team @MazeInBiotech with VA MVP demonstrating key piece of our approach: human genetics -> mechanism -> medicine See great thread below from @DrFlashHeart

Sharing exciting new work led by Adriana Hung, Alex Bick (@AlexBickMDPhD) and Eric Green (@ercgrn): Genetic inhibition of APOL1 Pore Forming Function Prevents APOL1-Mediated Kidney Disease A brief 🧵: journals.lww.com/jasn/fullte…

Post attachment
Sasha Gusev avatar
⟳ Eric Green retweeted
Sasha Gusev@SashaGusevPosts·16 Apr 2023

A 🧵 on some of my intuitions/priors about the genetics of complex and molecular traits in humans (i.e. what I think of as typical), largely motivated by GWAS/QTL studies over the past decade [citing papers with nice figures where possible]